Evidence map›Paper›PMID 31298539›Full record

ArticleJournal of medicinal chemistry2019

Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).

Xufen Yu, Xi-Ping Huang, Terry P Kenakin, Samuel T Slocum, Xin Chen, Michael L Martini, Jing Liu, Jian Jin

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Molecular basis of proton-sensing by G protein-coupled receptors.bioRxiv : the preprint server for biology · 2024
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xufen YuMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.
Xi-Ping Huang
Terry P Kenakin
Samuel T Slocum
Xin ChenMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.
Michael L MartiniMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.
Jing LiuMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.
Jian JinMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.ORCID 0000-0002-2387-3862
Icahn School of Medicine at Mount Sinai · USUniversity of North Carolina at Chapel Hill · US

Funding

MOUNT SINAI MEDICAL SCIENTIST TRAINING PROGRAMT32GM007280 · NIGMS · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BARON, MARGARET H · 1985 to 2021
$22.8M
Illuminating the Druggable GPCR-omeU24DK116195 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROTH, BRYAN L., SHOICHET, BRIAN K · 2017 to 2022
$14.3M
Teaching biomedical and pharmacological trainees to produce FAIR data for AI & ML applicationsT32GM062754 · NIGMS · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI SCHLESSINGER, AVNER · 2001 to 2023
$6.2M
Designing and developing PAM-antagonists for GPR68R21MH120422 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUANG, XI-PING, KENAKIN, TERRENCE PETER · 2019 to 2020
$460k
Designing and Developing Functionally Selective Allosteric Modulators for GPR68R56MH111769 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUANG, XI-PING, KENAKIN, TERRENCE PETER · 2017 to 2017
$420k
NIDDK NIH HHS U24 DK116195NIGMS NIH HHS T32 GM007280NIGMS NIH HHS T32 GM062754NIMH NIH HHS HHSN271201300017CNIMH NIH HHS R21 MH120422NIMH NIH HHS R56 MH111769
6 · The paper itself

Abstract

G protein-coupled receptor 68 (GPR68) is an understudied orphan G protein-coupled receptor (GPCR). It is expressed most abundantly in the brain, potentially playing important roles in learning and memory. Pharmacological studies with GPR68 have been hindered by lack of chemical tools that can selectively modulate its activity. We previously reported the first small-molecule positive allosteric modulator (PAM), ogerin (

Indexed as

Allosteric RegulationDrug DesignProtonsAnimalsBenzyl AlcoholsBlood-Brain BarrierCalciumHEK293 CellsHumansMiceMolecular StructureRadioligand AssayReceptors, G-Protein-CoupledStructure-Activity RelationshipTriazinesBenzyl AlcoholsCalciumGPR68 protein, humanGPR68 protein, mouseogerinProtonsReceptors, G-Protein-CoupledTriazines

Identifiers

PMID31298539
PMCPMC6923801
OpenAlexW2956853722

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.